Invest in Cytonics, the disruptive biotechnology revolutionizing a $180B Industry.
Cytonics is developing the world's first therapy that can tackle Osteoarthritis at the molecular level, helping to relieve aches and pains and inventing the future of joint relief.
Here are a few reasons to invest:
🔬 27M Americans currently suffering from Osteoarthritis and expected to affect 25% of the adult population by 2030
🔬 There’s currently no cure and no treatment addressing the root cause of Osteoarthritis, making Cytonics' therapy an industry-leading solution.
🔬 Raised $15M to date, including $4M from Synthes (a Johnson & Johnson company)
🔬 IP portfolio currently includes 8 U.S. and international patents with 9 more patents pending
With less than 1 month left, Cytonics is offering the general public an opportunity to invest - get in while you still can!
Invest now